AGT‑190 is an investigational re-engineered form of glial cell line-derived neurotrophic factor (GDNF) for the treatment of Parkinson’s disease (PD) and stroke. GDNF is a naturally occurring brain protein that has demonstrated neuroprotective effects in animal models. However, GDNF does not cross the BBB, and current forms must be delivered directly into the cerebrum to be effective.
AGT-190, a neurotrophin fusion molecule, crosses the BBB via receptor-mediated transport.1
Preclinical validation studies of AGT-190 are ongoing in PD and stroke.
1 Zhou Q-H, et al. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab Dispos. 2010;38:566-572